1. ALLA AKTIER
  2. NYHETER
  3. LIPUM

Lipum

Nyheter Lipum Nyheter alla bolag

Lipum to participate in following upcoming

Lipum (publ), a clinical stage biopharmaceutical company developing the drug candidate SOL-116 focused on chronic inflammatory diseases, today announced its participation in the following upcoming events.

Stora Aktiedagarna | 5 March | Stockholm, Sweden

Redeye Investor Forum Online | 7 March | Digital

Biostock Health and Wealth | 11-15 March | Digital

BIO-Europe Spring | 18-20 March | Barcelona, Spain

LSX World Congress | 29-30 April | London, UK

“I am looking forward to these meetings. The first part of the clinical phase 1 study has been completed with positive results and the industry meetings provide great opportunities to present our progress. " says CEO Ola Sandborgh

Contacts
Ola Sandborgh, CEO
ola.sandborgh@lipum.se
+46 72 218 80 21
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
Lipum to participate in following upcoming

Datum 2024-02-13, kl 13:00
Källa MFN
Bifogade filer
Lipum to participate in following upcoming
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!